European external quality control study on the competence of laboratories to recognize rare sequence variants resulting in unusual genotyping results

Clinical Chemistry

Volumn 55, Issue 4, 2009, Pages 739-747

  Márki Zay, János ^a,b   Klein, Christoph L ^a   Gancberg, David ^a,c   Schimmel, Heinz G ^a   Dux, Laszlo ^b,d  

^a JOINT RESEARCH CENTRE   (Italy)

^b UNIVERSITY OF SZEGED   (Hungary)

^c EUROPEAN COMMISSION   (Belgium)

^d QualiCont   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

PROTHROMBIN;

ALLELE; ARTICLE; DIAGNOSTIC ACCURACY; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; LABORATORY DIAGNOSIS; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; QUALITY CONTROL; SINGLE NUCLEOTIDE POLYMORPHISM; SITE DIRECTED MUTAGENESIS; DIAGNOSIS, MEASUREMENT AND ANALYSIS; DNA SEQUENCE; EUROPE; HUMAN; LABORATORY; METHODOLOGY; STATISTICS; TRANSITION TEMPERATURE;

EUROPE; GENOTYPE; HUMANS; LABORATORIES; LABORATORY TECHNIQUES AND PROCEDURES; QUALITY CONTROL; SEQUENCE ANALYSIS, DNA; TRANSITION TEMPERATURE;

EID: 64149116384     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2008.112102     Document Type: Article

References (35)

1. Teupser D, Rupprecht W, Lohse P, Thiery J. Fluorescence-based detection of the CETP TaqIB polymorphism: false positives with the TaqMan- based exonuclease assay attributable to a previ- ously unknown gene variant. Clin Chem 2001;47: 852-7.
2. Lay MJ, Wittwer CT. Real-time fluorescence geno- typing of factor V Leiden during rapid-cycle PCR. Clin Chem 1997;43:2262-7.
3. Jeffrey GP, Chakrabarti S, Hegele RA, Adams PC. Polymorphism in intron 4 of HFE may cause over- estimation of C282Y homozygote prevalence in haemochromatosis. Nat Genet 1999;22:325-6.
4. Lyon E. Discovering rare variants by use of melt- ing temperature shifts seen in melting curve anal- ysis [Editorial]. Clin Chem 2005;51:1331-2.
5. Graham R, Liew M, Meadows C, Lyon E, Wittwer CT. Distinguishing different DNA heterozygotes by high-resolution melting. Clin Chem 2005;51: 1295-8.
6. Mahadevan MS, Benson PV. Factor V null muta- tion affecting the Roche LightCycler factor V Lei- den assay. Clin Chem 2005;51:1533-5.
7. Liew M, Pryor R, Palais R, Meadows C, Erali M, Lyon E, et al. Genotyping of single nucleotide polymorphisms by high-resolution melting of small amplicons. Clin Chem 2004;50:1156-64.
8. Lyon E, Millson A, Phan T, Wittwer CT. Detection and identification of base alterations within the region of factor V Leiden by fluorescent melting curves. Mol Diagn 1998;3:203-10.
9. Phillips M, Meadows CA, Huang MY, Millson A, Lyon E. Simultaneous detection of C282Y and H63D hemochromatosis mutations by dual-color probes. Mol Diagn 2000;5:107-16.
10. Tag CG, Gressner AM, Weiskirchen R. An unusual melting curve profile in LightCycler multiplex genotyping of the hemochromatosis H63D/C282Y gene mutations. Clin Biochem 2001;34:511-5.
11. Warshawsky I, Hren C, Sercia L, Shadrach B, Deitcher SR, Newton E, et al. Detection of a novel point mutation of the prothrombin gene at posi- tion 20209. Diagn Mol Pathol 2002;11:152-6.
12. Wylenzek M, Geisen C, Stapenhorst L, Wielckens K, Klingler KR. A novel point mutation in the 3 region of the prothrombin gene at position 20221 in a Lebanese/Syrian family [Letter]. Thromb Hae- most 2001;85:943-4.
13. Schrijver I, Lenzi TJ, Jones CD, Lay MJ, Druzin ML, Zehnder JL. Prothrombin gene variants in non- Caucasians with fetal loss and intrauterine growth retardation. J Mol Diagn 2003;5:250-3.
14. Tag CG, Schifflers M-C, Mohnen M, Gressner AM, Weiskirchen R. Atypical melting curve resulting from genetic variation in the 3-untranslated re- gion at position 20218 in the prothrombin gene analyzed with the LightCycler factor II (prothrom- bin) G20210A assay [Letter]. Clin Chem 2005;51: 1560-1.
15. Klein CL, Márki-Zay J, Corbisier P, Gancberg D, Cooper S, Gemmati D, et al. Reference materials (RMs) for analysis of the human factor II (pro- thrombin) gene G20210A mutation. Clin Chem Lab Med 2005;43:862-8.
16. Gancberg D, Márki-Zay J, Corbisier P, Klein C, Schimmel H, Emons H. Certification of a reference material consisting of purified plasmid DNA con- taining a fragment from the human prothrombin gene (wildtype): certified reference material IRMM/IFCC-490. Geel (Belgium): European Com- mission, Directorate-General Joint Research Cen- tre, Institute for Reference Materials and Measurements; 2006. 35 p. Report EUR 22169 EN.
17. Gancberg D, Márki-Zay J, Corbisier P, Klein C, Schimmel H, Emons H. Certification of a reference material consisting of purified plasmid DNA con- taining a fragment from the human prothrombin gene (G20210A mutant): certified reference ma- terial IRMM/IFCC-491. Geel (Belgium): European Commission, Directorate-General Joint Research Centre, Institute for Reference Materials and Measurements; 2006. 35 p. Report EUR 22170 EN.
18. Gancberg D, Márki-Zay J, Corbisier P, Klein C, Schimmel H, Emons H. Certification of a reference material consisting of purified plasmid DNA con- taining a fragment from the human prothrombin gene (heterozygous G20210 wildtype/G20210A mutant): certified reference material IRMM/IFCC- 492. Geel (Belgium): European Commission, Directorate-General Joint Research Centre, Insti- tute for Reference Materials and Measurements; 2006. 33 p. Report EUR 22167 EN.
19. Gancberg D, Corbisier P, Meeus N, Marki-Zay J, Mannhalter C, Schimmel H. Certification of refer- ence materials for detection of the human pro- thrombin gene G20210A sequence variant. Clin Chem Lab Med 2008;46:463-9.
20. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3- untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-703.
21. McGlennen RC, Key NS. Clinical and laboratory management of the prothrombin G20210A mu- tation. Arch Pathol Lab Med 2002;126:1319-25.
22. Wylenzek C, Trubenbach J, Gohl P, Wildhardt G, Alkins S, Fausett MB, et al. Mutation screening for the prothrombin variant G20210A by melting point analysis with the LightCycler system: atyp- ical results, detection of the variant C20209T and possible clinical implications. Clin Lab Haematol 2005;27:343-6.
23. Clench T, Standen GR, Ryan E, Chilcott JL, Mum- ford AD. Rapid detection of the prothrombin C20209T transition by LightCycler analysis. Thromb Haemost 2005;94:1114-5.
24. van der Putten HH, Spaargaren-van Riel CC, Ber- tina RM, Vos HL. Functional analysis of two pro- thrombin 3-untranslated region variants: the C20209T variant, mainly found among African- Americans, and the C20209A variant. J Thromb Haemost 2006;4:2285-7.
25. Meadows CA, Warner D, Page S, Lyon E. Detec- tion of novel mutation using fluorescent hybrid- ization probes and melting temperature analysis [Abstract]. J Mol Diagn 2001;3:195.
26. Jennings I, Kitchen S, Woods TA, Preston FE. Multilaboratory testing in thrombophilia through the United Kingdom National External Quality Assessment Scheme (Blood Coagulation) Quality Assurance Program. Semin Thromb Hemost 2005; 31:66-72.
27. Tripodi A, Chantarangkul V, Menegatti M, Taglia- bue L, Peyvandi F. Performance of clinical labo- ratories for DNA analyses to detect thrombophilia mutations. Clin Chem 2005;51:1310-1.
28. Neumaier M, Braun A, Gessner R, Funke H. Ex- periences with external quality assessment (EQA) in molecular diagnostics in clinical laboratories in Germany. Working Group of the German Societ- ies for Clinical Chemistry (DGKC) and Laboratory Medicine. Clin Chem Lab Med 2000;38:161-3.
29. Tripodi A, Peyvandi F, Chantarangkul V, Me- negatti M, Mannucci PM. Relatively poor perfor- mance of clinical laboratories for DNA analyses in the detection of two thrombophilic mutations: a cause for concern. Thromb Haemost 2002;88: 690-1.
30. Danneberg J, Abbes AP, Bruggeman BJ, Engel H, Gerrits J, Martens A. Reliable genotyping of the G-20210-A mutation of coagulation factor II (pro- thrombin). Clin Chem 1998;44:349-51.
31. Spector EB, Grody WW, Matteson CJ, Palomaki GE, Bellissimo DB, Wolff DJ, et al. Technical standards and guidelines: venous thromboembo- lism (factor V Leiden and prothrombin 20210G A testing): a disease-specific supplement to the standards and guidelines for clinical genetics lab- oratories. Genet Med 2005;7:444-53.
32. Chen B, O'Connell CD, Boone DJ, Amos JA, Beck JC, Chan MM, et al. Developing a sustainable process to provide quality control materials for genetic testing. Genet Med 2005;7:534-49.
33. Richards CS, Bale S, Bellissimo DB, Das S, Grody WW, Hegde MR, et al., Molecular Subcommittee 746 Proficiency Testing Study on Rare Sequence Variants of the ACMG Laboratory Quality Assurance Com- mittee. ACMG recommendations for standards for interpretation and reporting of sequence variations: revisions 2007. Genet Med 2008;10: 294-300.
34. Ahmad-Nejad P, Dorn-Beineke A, Pfeiffer U, Brade J, Geilenkeuser WJ, Ramsden S, et al. Methodologic European external quality assur- ance for DNA sequencing: the EQUALseq pro- gram. Clin Chem 2006;52:716-27.
35. Dorn-Beineke A, Ahmad-Nejad P, Pfeiffer U, Rams- den S, Pazzagli M, Neumaier M. Improvement of technical and analytical performance in DNA se- quencing by external quality assessment-based molecular training. Clin Chem 2006;52:2072-8.